Adolor Corporation (NasdaqGM: ADLR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel prescription pain management products. Adolor's mission addresses a simple goal: to provide enhanced relief for the millions of people who suffer from pain each year.

The Company commenced operations in 1994 to capitalize on proprietary technology in cloned opioid receptors.  Today, the Company is a leader in the discovery and development of novel opioid receptor-targeted therapeutics designed to maintain or improve opioid-like pain relief and reduce opioid side effects.

Adolor’s  first commercial product, ENTEREG® (alvimopan), is a peripherally-acting mu opioid receptor antagonist intended to block the negative effects of opioids, like morphine, on the gastrointestinal (GI) tract without interfering with central nervous system (CNS) mediated analgesia. ENTEREG is the first FDA-approved therapy for the management of postoperative ileus (POI) following bowel resection surgery.  The product is specifically indicated to accelerate upper and lower GI recovery following partial large or small bowel resection surgery with primary anastomosis.

POI is the impairment of GI motility after intra-abdominal surgery or other non-abdominal surgeries.  It is associated with abdominal distension and bloating, persistent abdominal pain, nausea and vomiting, variable reduction of bowel sounds, delayed passage of or an inability to pass flatus (gas) or stool and an inability to tolerate oral intake or progress to a solid diet.  POI may potentially delay GI recovery and hospital discharge until its resolution, resulting in decreased patient quality of life, increased medical care and an increased cost burden on healthcare providers.

ENTEREG was approved subject to a Risk Evaluation and Mitigation Strategy (REMS) and the product labeling carries a boxed warning that ENTEREG is available only for short-term (15 doses) use in hospitalized patients.  Under the REMS, ENTEREG is available only to hospitals that perform bowel resection surgeries and that are enrolled in the ENTEREG Access Support and Education (E.A.S.E.™) Program.

Adolor is collaborating with GlaxoSmithKline (GSK) on the commercialization of ENTEREG in the United States.

The Company also has an exclusive worldwide collaboration with Pfizer, Inc. to develop and commercialize two of Adolor’s proprietary delta opioid receptor agonist compounds, ADL5859 and ADL5747 (Pfizer compounds PF-04856880 and PF-04856881, respectively), for the treatment of pain in a wide range of conditions.  These compounds selectively stimulate the delta opioid receptor and may represent a potential new class of opioid analgesics that produce pain relief similar to traditional mu opioids, while reducing or eliminating some typical narcotic side effects.

A third development program focuses on the condition of opioid bowel dysfunction, a frequent consequence of chronic opioid use for pain.

There are two compounds in development, ADL7445 and ADL5945, to treat OBD. These compounds are small molecule, mu opioid receptor antagonists intended to block the adverse effects of opioid analgesics on the GI tract without affecting analgesia. Adolor submitted an Investigational New Drug Application (IND) for ADL7445 in September 2009 and initiated clinical evaluation of this compound in November of 2009. ADL5945 was acquired from Eli Lilly in September 2009 and Adolor intends to initiate clinical testing of this compound in early 2010.

By applying its knowledge and expertise in pain management, along with ingenuity, Adolor Corporation is seeking to make a positive difference for patients, caregivers and the medical community.